|
Transgene Biotek was incorporated as a private limited company in Mar.'90 and was converted into a public limited company in Nov.'90.The company is engaged in the research and development and manufacture of various medical reagents both chemical and immuno-diagnostic reagents for the qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.Transgene Biotek's products are exported to Africa Russia China Malaysia and the Phillipines. The company chalked out a new project for setting up a manufacturing facility at a cost of Rs.30 crore at the Anrich Industrial AreaBollaram. TBL is working of four new plants:Oral deliver of proteins and peptides:DNA vaccines:fusion proteins and bio therapeutics. The new project is being funded by way of preferential offer to Batterymarch Financial management USA and other financial institutions. |
Transgene Biotek Ltd.
| BSE: 526139 | Sector: Health care |
| NSE: N.A. | ISIN Code: INE773D01018 |
| BSE 15:01 | 27 Jan | 3.58 |
0.16 (4.68%) |
OPEN
3.42 |
HIGH
3.59 |
LOW
3.25 |
| NSE 05:30 | 01 Jan | Transgene Biotek Ltd |
| OPEN | 3.42 |
| PREVIOUS CLOSE | 3.42 |
| VOLUME | 20890 |
| 52-Week high | 5.93 |
| 52-Week low | 3.03 |
| P/E | |
| Mkt Cap.(Rs cr) | 27 |
| Buy Price | 3.30 |
| Buy Qty | 90.00 |
| Sell Price | 3.58 |
| Sell Qty | 3045.00 |
Transgene Biotek Ltd. (TRANSGENEBIOTEK) - Company History
Quick Links for Transgene Biotek:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
